Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002654669 | SCV003521625 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-05-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004992547 | SCV005598293 | uncertain significance | Cardiovascular phenotype | 2024-12-05 | criteria provided, single submitter | clinical testing | The c.3410A>G (p.K1137R) alteration is located in exon 26 (coding exon 26) of the JAG1 gene. This alteration results from a A to G substitution at nucleotide position 3410, causing the lysine (K) at amino acid position 1137 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004550446 | SCV004113053 | uncertain significance | JAG1-related disorder | 2024-02-17 | no assertion criteria provided | clinical testing | The JAG1 c.3410A>G variant is predicted to result in the amino acid substitution p.Lys1137Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0099% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |